Meta-analysis: amantadine may lower the efficacy of pegylated interferon plus ribavirin in treatment-naive hepatitis C genotype 1 patients | Zendy

Jian Chen | Zendy; Jian Shi | Zendy; WeiFen Xie | Zendy; Xin Zeng | Zendy; Yong Lin | Zendy

Open Access

Meta-analysis: amantadine may lower the efficacy of pegylated interferon plus ribavirin in treatment-naive hepatitis C genotype 1 patients

Author(s) -

Jian Chen,

Jian Shi,

WeiFen Xie,

Xin Zeng,

Yong Lin

Publication year - 2012

Publication title -

international journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.278

H-Index - 89

eISSN - 1878-3511

pISSN - 1201-9712

DOI - 10.1016/j.ijid.2012.06.002

Subject(s) - ribavirin , amantadine , pegylated interferon , medicine , hepatitis c , virology , genotype , pharmacology , gastroenterology , chronic hepatitis , virus , biology , biochemistry , gene

The current standard therapy for hepatitis C virus genotype 1 (HCV-1) infection is still suboptimal. Whether adding amantadine (AMA) to pegylated interferon (PEG-IFN) plus ribavirin (RBV) improves the virological response in treatment-naive HCV-1 patients remains unclear.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research